World's Best Scientists 2026 revealed!
Award Badge
Medicine
Taiwan
2026

D-Index & Metrics

Medicine

D-Index
106
Citations
73391
World Ranking
6360
National Ranking
11

Research.com Recognitions

  • 2026 - Research.com Medicine in Taiwan Leader Award
  • 2023 - Research.com Medicine in Taiwan Leader Award
  • 2022 - Research.com Medicine in Taiwan Leader Award
  • 2007 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Ann-Lii Cheng is affiliated with National Taiwan University in Taiwan and has extensively contributed to the field of medicine, with a particular focus on oncology and hepatology. Their scholarly work primarily addresses the treatment and prognosis of hepatocellular carcinoma, cancer immunotherapy, biomarkers, and various aspects of liver disease diagnosis and treatment.

Their research spans multiple specialized subfields, including oncology, hepatology, pulmonary and respiratory medicine, epidemiology, and pathology and forensic medicine. This interdisciplinary approach allows for comprehensive studies on cancer mechanisms, viral hepatitis, and hepatic oncology.

Notable recent publications by Ann-Lii Cheng include:

  • "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma," 2020, New England Journal of Medicine
  • "Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma," 2021, Journal of Hepatology
  • "Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma," 2020, Journal of Hepatology

Their work features collaboration with frequent co-authors such as Masatoshi Kudo, Richard S. Finn, Philippe Merle, Peter R. Galle, and Shukui Qin, reflecting a network of researchers involved in hepatocellular carcinoma and cancer immunotherapy studies.

Ann-Lii Cheng has published extensively in several scientific journals, with significant publications appearing in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • Liver Cancer
  • Journal of Hepatology

Their research topics cover a broad spectrum related to cancer and liver diseases, including:

  • Hepatocellular carcinoma treatment and prognosis
  • Cancer immunotherapy and biomarkers
  • Colorectal cancer treatments and studies
  • Cancer mechanisms and therapy
  • Pancreatic and hepatic oncology research
  • Hepatitis B virus studies
  • Liver disease diagnosis and treatment

Ann-Lii Cheng has been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 2007, indicating a level of professional acknowledgment within the scientific community.

Best Publications

  • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

    Ann Lii Cheng;Yoon Koo Kang;Zhendong Chen;Chao Jung Tsao

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

    Cheng Al;Hsu Ch;Lin Jk;Hsu Mm

  • Stability of curcumin in buffer solutions and characterization of its degradation products

    Ying-Jan Wang;Min-Hsiung Pan;Ann-Lii Cheng;Liang-In Lin

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Tim Meyer;Ann Lii Cheng;Anthony B. El-Khoueiry

  • Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

    Masao Omata;Ann Lii Cheng;Norihiro Kokudo;Masatoshi Kudo

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

    Masao Omata;Laurentius A. Lesmana;Ryosuke Tateishi;Pei Jer Chen

  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

    Jordi Bruix;Ann-Lii Cheng;Gerold Meinhardt;Keiko Nakajima

  • CLINICAL STUDIES WITH CURCUMIN

    Chih-Hung Hsu;Ann-Lii Cheng

  • Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

    Ann-Lii Cheng;Chiun Hsu;Stephen L. Chan;Su-Pin Choo

  • Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

    Kuen-Feng Chen;Hui-Ling Chen;Wei-Tien Tai;Wen-Chi Feng

  • Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.

    Ann Lii Cheng;Chao A. Hsiung;Ih Jen Su;Pei Jer Chen;Pei Jer Chen

  • A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial

    Chiun Hsu;Chao A. Hsiung;Ih Jen Su;Wei Shou Hwang

Frequent Co-Authors

Masatoshi Kudo
Masatoshi Kudo Kindai University
Pei-Jer Chen
Pei-Jer Chen National Taiwan University
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Ih-Jen Su
Ih-Jen Su National Health Research Institutes
Ming-Shiang Wu
Ming-Shiang Wu National Taiwan University
Stephen L. Chan
Stephen L. Chan Chinese University of Hong Kong
Andrew X. Zhu
Andrew X. Zhu Harvard University
Jaw-Town Lin
Jaw-Town Lin E-Da Hospital
Ho Yeong Lim
Ho Yeong Lim Samsung Medical Center
Chun-Yu Liu
Chun-Yu Liu Boston University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want flexibility or alternative pathways, several online health degrees can help you get started. For those interested in patient care but who wish to avoid standardized entrance exams, there are nursing programs without teas requirements, making entry into nursing more accessible.

Students interested in the administrative side of healthcare may want to explore reputable healthcare administration degrees. These programs are available online and can prepare graduates for management or organizational roles within hospitals or clinics.

For nurses looking to advance their credentials, there are also bridge options like asn to np programs, which allow registered nurses to become nurse practitioners via flexible, accelerated courses.

Finally, if you’re passionate about diet, wellness, and public health, several online nutrition degree programs can help you enter this fast-growing field.

Each pathway offers unique opportunities and can be a step toward a fulfilling career in healthcare—even if you aren't pursuing traditional medical school.

Best Scientists Citing Ann-Lii Cheng

Trending Scientists